We suggest that if someone with CML lives sufficiently long this founding LSC will produce a BCR::ABL1-positive CD4-positive T-cell which will form a benign clone that will protect him/her against neoplastic LSCs. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.